Patient Resources

Interested in a home infusion support program? Talk to your hemophilia treatment team for more information.

Usual dose:

As dosage and treatment duration depend on your clinical situation, the type and severity of your bleeding and your FVIII:C levels, your physician will decide on your treatment on an individual basis.

General dosing recommendations:

• For a minor bleeding episode: 20–40 IU/kg body weight.
• For a moderate/major bleeding episode: 30–60 IU/kg body weight.
• For a life-threatening bleeding episode: 60–100 IU/kg body weight.
• For a minor surgical procedure: 30–60 IU/kg body weight for at least 1 day.
• For a major surgical procedure: 80–100 IU/kg body weight before and after surgery.
• Long-term prophylaxis against bleeding for adults is 30-40 IU/kg of body weight every other day.
• Regular prophylaxis schedule for children is 30-40 IU/kg of body weight every other day or 3 times per week.

Overdose:

No symptom of overdose has been reported.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

It is important to take the total daily dose prescribed to ensure you get maximum benefit. If you miss a dose, take the missed dose as soon as possible, and then continue as before. However, if a dose is skipped, do not double the next dose. Continue on with your normal dose on the regular schedule as prescribed by your doctor.

Talk to your hemophilia treatment team for guidance on optimal Nuwiq dosing for your needs.

Allergic reactions such as hives and itching can occur at the injection site with Nuwiq®. If these symptoms occur contact your doctor or pharmacist for advice before continuing treatment. In rare cases, the allergic reactions are severe, known as shock or anaphylactic shock. This may include extreme difficulty breathing, or loss of consciousness. Urgent treatment is required and the emergency services should be called, for example 911.

Development of inhibitors is a known complication in the treatment of hemophilia A.
Inhibitors are antibodies that block the activity of factor VIII, reducing the efficacy of Nuwiq® in prevention or control of bleeding. If your bleeding is not controlled with Nuwiq®, tell your doctor immediately. Tests should be performed to determine if the inhibitors are present.

This is not a complete list of side effects.

For any unexpected effects while taking Nuwiq®, contact your doctor,  hemophilia nurse or pharmacist. You can also report suspected side effects directly to the Canada Vigilance Program by calling 1-866-234-2345.